Genetic causes of canine mast cell tumours (MCTs), except for mutations in the KIT gene detected in some MCTs, are generally unknown. We used whole exome sequencing to reveal mutation spectra in canine MCTs. We detected somatic mutations in 87 genes including 10 genes recognized as human cancer drivers. Besides KIT, 14 other genes were recurrently mutated. Subsequently, we performed next generation sequencing of a panel of 50 selected genes in additional MCT samples. In this group, the most frequently altered gene was GNB1 showing a recurrent dinucleotide substitution at position of Gly116 in 30% of the MCT samples (n = 6/20) and Ile80 substitution accompanied by a splice region mutation in one case. We extended the study by analysis of the above mentioned GNB1 regions in additional MCT samples by Sanger sequencing, and assessed the overall prevalence of GNB1 mutations to 17.3% (n = 14/81), which is similar to the prevalence of KIT alterations. Our results indicate that GNB1 mutations are probably involved in canine MCT pathogenesis in both cutaneous and subcutaneous MCT cases. As opposed to KIT alterations, the presence of GNB1 mutations did not negatively affect survival times, and our data even showed a trend towards positive prognosis. If our results are confirmed in a larger number of MCTs, an extension of molecular testing of canine MCTs by GNB1 analysis would help to refine the molecular stratification of MCTs, and become useful for targeted treatment strategies.

Central European Institute of Technology Masaryk University Brno Czech Republic

Department of Genetics and Reproduction Central European Institute of Technology Veterinary Research Institute Brno Czech Republic

Department of Pathological Morphology and Parasitology Faculty of Veterinary Medicine University of Veterinary and Pharmaceutical Sciences Brno Czech Republic

See more in PubMed

Carter MC, Metcalfe DD, Komarow HD. Mastocytosis. Immunol Allergy Clin N Am. 2014;34:181-196.

London CA, Seguin B. Mast cell tumors in the dog. Vet Clin N Am Small Anim Pract. 2003;33:473-489.

Blackwood L, Murphy S, Buracco P, et al. European consensus document on mast cell tumours in dogs and cats. Vet Comp Oncol. 2012;10:e1-e29.

Patnaik AK, Ehler WJ, MacEwen EG. Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs. Vet Pathol. 1984;21:469-474.

Kiupel M, Webster JD, Bailey KL, et al. Proposal of a 2-tier histologic grading system for canine cutaneous mast cell tumors to more accurately predict biological behavior. Vet Pathol. 2011;48:147-155.

Garcia-Montero AC, Jara-Acevedo M, Teodosio C, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood. 2006;108:2366-2372.

London CA, Galli SJ, Yuuki T, Hu ZQ, Helfand SC, Geissler EN. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Exp Hematol. 1999;27:689-697.

Letard S, Yang Y, Hanssens K, et al. Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors. Mol Cancer Res. 2008;6:1137-1145.

Takeuchi Y, Fujino Y, Watanabe M, et al. Validation of the prognostic value of histopathological grading or c-kit mutation in canine cutaneous mast cell tumours: a retrospective cohort study. Vet J 1997. 2013;196:492-498.

Webster JD, Yuzbasiyan-Gurkan V, Kaneene JB, Miller R, Resau JH, Kiupel M. The role of c-KIT in tumorigenesis: evaluation in canine cutaneous mast cell tumors. Neoplasia. 2006;8:104-111.

London CA, Malpas PB, Wood-Follis SL, et al. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin Cancer Res Off J Am Assoc Cancer Res. 2009;15:3856-3865.

Bonkobara M. Dysregulation of tyrosine kinases and use of imatinib in small animal practice. Vet J 1997. 2015;205:180-188.

Zorzan E, Hanssens K, Giantin M, Dacasto M, Dubreuil P. Mutational hotspot of TET2, IDH1, IDH2, SRSF2, SF3B1, KRAS, and NRAS from human systemic mastocytosis are not conserved in canine mast cell tumors. PLoS One. 2015;10:e0142450.

Vozdova M, Kubickova S, Fictum P, et al. Prevalence and prognostic value of c-kit and TP53 mutations in canine mast cell tumours. Vet J. 2019;247:71-74.

Thompson JJ, Pearl DL, Yager JA, Best SJ, Coomber BL, Foster RA. Canine subcutaneous mast cell tumor: characterization and prognostic indices. Vet Pathol. 2011;48:156-168.

Thompson JJ, Morrison JA, Pearl DL, et al. Receptor tyrosine kinase expression profiles in canine cutaneous and subcutaneous mast cell tumors. Vet Pathol. 2016;53:545-558.

Vozdova M, Kubickova S, Fictum P, et al. Mutation and methylation status of KIT and TP53 in canine cutaneous and subcutaneous mast cell tumours. Vet Comp Oncol. 2019; 1-7. https://doi.org/10.1111/vco.12543.

Okonechnikov K, Conesa A, García-Alcalde F. Qualimap 2: advanced multi-sample quality control for high-throughput sequencing data. Bioinformatics. 2016;32:292-294.

McLaren W, Gil L, Hunt SE, et al. The Ensembl variant effect predictor. Genome Biol. 2016;17:122.

Diaz M, Flajnik MF, Klinman N. Evolution and the molecular basis of somatic hypermutation of antigen receptor genes. Philos Trans R Soc Lond Ser B. 2001;356:67-72.

Futreal PA, Coin L, Marshall M, et al. A census of human cancer genes. Nat Rev Cancer. 2004;4:177-183.

Downing S, Chien MB, Kass PH, Moore PE, London CA. Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-kit in mast cell tumors of dogs. Am J Vet Res. 2002;63:1718-1723.

Giantin M, Vascellari M, Morello EM, et al. c-KIT messenger RNA and protein expression and mutations in canine cutaneous mast cell tumors: correlations with post-surgical prognosis. J Vet Diagn Invest. 2012;24:116-126.

Marconato L, Zorzan E, Giantin M, Di Palma S, Cancedda S, Dacasto M. Concordance of c-kit mutational status in matched primary and metastatic cutaneous canine mast cell tumors at baseline. J Vet Intern Med. 2014;28:547-553.

Tamlin VS, Kessell AE, Mccoy RJ, et al. Prevalence of exon 11 internal tandem duplications in the C-KIT proto-oncogene in Australian canine mast cell tumours. Aust Vet J. 2017;95:386-391.

Takeuchi Y, Bonkobara M. Receptor tyrosine kinase KIT: prognostic and therapeutic involvement in canine mast cell tumours. Vet J 1997. 2016;210:5-6.

Webster JD, Yuzbasiyan-Gurkan V, Miller RA, Kaneene JB, Kiupel M. Cellular proliferation in canine cutaneous mast cell tumors: associations with c-KIT and its role in prognostication. Vet Pathol. 2007;44:298-308.

Wang Z, Sun P, Gao C, et al. Down-regulation of LRP1B in colon cancer promoted the growth and migration of cancer cells. Exp Cell Res. 2017;357:1-8.

Cowin PA, George J, Fereday S, et al. LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin. Cancer Res. 2012;72:4060-4073.

Chung NS, Wasan KM. Potential role of the low-density lipoprotein receptor family as mediators of cellular drug uptake. Adv Drug Deliv Rev. 2004;56:1315-1334.

Li F, Mao G, Tong D, et al. The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSα. Cell. 2013;153:590-600.

Yuan H, Li N, Fu D, et al. Histone methyltransferase SETD2 modulates alternative splicing to inhibit intestinal tumorigenesis. J Clin Invest. 2017;127:3375-3391.

Kim I-K, McCutcheon JN, Rao G, et al. Acquired SETD2 mutation and impaired CREB1 activation confer cisplatin resistance in metastatic non-small cell lung cancer. Oncogene. 2019;38:180-193.

Bailey MH, Tokheim C, Porta-Pardo E, et al. Comprehensive characterization of cancer driver genes and mutations. Cell. 2018;173:371-385.e18.

Bouaoun L, Sonkin D, Ardin M, et al. TP53 variations in human cancers: new lessons from the IARC TP53 database and genomics data. Hum Mutat. 2016;37:865-876.

Katoh M. Function and cancer genomics of FAT family genes (review). Int J Oncol. 2012;41:1913-1918.

Wong K, van der Weyden L, Schott CR, et al. Cross-species genomic landscape comparison of human mucosal melanoma with canine oral and equine melanoma. Nat Commun. 2019;10:353.

Zhang R, Song C. Loss of CSMD1 or 2 may contribute to the poor prognosis of colorectal cancer patients. Tumour Biol. 2014;35:4419-4423.

Shen Z. Genomic instability and cancer: an introduction. J Mol Cell Biol. 2011;3:1-3.

Abbas T, Keaton MA, Dutta A. Genomic instability in cancer. Cold Spring Harb Perspect Biol. 2013;5:a012914.

Ferguson LR, Chen H, Collins AR, et al. Genomic instability in human cancer: molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition. Semin Cancer Biol. 2015;35:S5-S24.

Campbell BB, Light N, Fabrizio D, et al. Comprehensive analysis of hypermutation in human cancer. Cell. 2017;171(5):1042-1056.e10.

Schwaab J, Schnittger S, Sotlar K, et al. Comprehensive mutational profiling in advanced systemic mastocytosis. Blood. 2013;122(14):2460-2466.

Valent P. Diagnosis and management of mastocytosis: an emerging challenge in applied hematology. Hematol Am Soc Hematol Educ Prog. 2015;2015(1):98-105.

Zhu N, Xiao H, Wang L-M, Fu S, Zhao C, Huang H. Mutations in tyrosine kinase and tyrosine phosphatase and their relevance to the target therapy in hematologic malignancies. Future Oncol Lond Engl. 2015;11(4):659-673.

Ford CE, Skiba NP, Bae H, et al. Molecular basis for interactions of G protein βγ subunits with effectors. Science. 1998;280(5367):1271-1274.

Buljan M, Blattmann P, Aebersold R, Boutros M. Systematic characterization of pan-cancer mutation clusters. Mol Syst Biol. 2018;14(3):e7974.

Wazir U, Jiang WG, Sharma AK, Mokbel K. Guanine nucleotide binding protein β 1: a novel transduction protein with a possible role in human breast cancer. Cancer Genomics Proteomics. 2013;10(2):69-73.

Yoda A, Adelmant G, Tamburini J, et al. GNB1 activating mutations promote myeloid and lymphoid neoplasms targetable by combined PI3K/mTOR inhibition. Blood. 2014;124(21):3567-3567.

Yoda A, Adelmant G, Tamburini J, et al. Mutations in G protein β subunits promote transformation and kinase inhibitor resistance. Nat Med. 2015;21(1):71-75.

Hemati P, Revah-Politi A, Bassan H, et al. Refining the phenotype associated with GNB1 mutations: clinical data on 18 newly identified patients and review of the literature. Am J Med Genet A. 2018;176(11):2259-2275.

Arendt ML, Melin M, Tonomura N, et al. Genome-wide association study of golden retrievers identifies germ-line risk factors predisposing to mast cell tumours. PLoS Genet. 2015;11(11):e1005647.

Szczałuba K, Biernacka A, Szymańska K, et al. Novel GNB1 de novo mutation in a patient with neurodevelopmental disorder and cutaneous mastocytosis: clinical report and literature review. Eur J Med Genet. 2018;61(3):157-160.

Zimmermannova O, Doktorova E, Stuchly J, et al. An activating mutation of GNB1 is associated with resistance to tyrosine kinase inhibitors in ETV6-ABL1-positive leukemia. Oncogene. 2017;36(43):5985-5994.

Weishaar KM, Ehrhart EJ, Avery AC, et al. C-kit mutation and localization status as response predictors in mast cell tumors in dogs treated with prednisone and toceranib or vinblastine. J Vet Intern Med. 2018;32(1):394-405.

London CA, Hannah AL, Zadovoskaya R, et al. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res. 2003;9(7):2755-2768.

Thompson JJ, Yager JA, Best SJ, et al. Canine subcutaneous mast cell tumors: cellular proliferation and KIT expression as prognostic indices. Vet Pathol. 2011;48(1):169-181.

[[dataset 1]] Vozdova M, Kubickova S, Pal K, Fröhlich J, Fictum P, Rubes J; 2019; Canine mast cell tumour sequencing; NCBI SRA; PRJNA518003.

[[dataset 2]] Vozdova M, Kubickova S, Pal K, Fröhlich J, Fictum P, Rubes J; 2019; Canine mast cell tumour gene panel sequencing; NCBI SRA; PRJNA576344.